RxDoctor Payments DataLook up a doctor →

Chad Shelton, MD

Pain Medicine · Saint Peters, MONPI 1194758938

Payments from drug & device makers

$18,497in general payments, 2019–2025

Across 505 payments — averaging $36.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertiflex, Inc.$2K
  • Abbott$2K
  • Spinal Simplicity, LLC$2K
  • Relievant Medsystems, Inc.$1K
  • Boston Scientific$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $8K from 49 others

What the payments were for

  • Travel & lodging$4,70725%
  • Food & beverage$13,75774%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,497 in reported general payments places this provider in the 85th percentile of 124 pain medicine providers in Missouri.

See all pain medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$231,839
Medicare patients
383
Services billed
3,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl46$23,420
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen576$17,811
Buprenorphine87$15,650
OxycontinOxycodone Hcl28$14,319
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen591$14,181
GraliseGabapentin12$13,105
NucyntaTapentadol Hcl14$10,271
Xtampza ErOxycodone Myristate17$9,506
MovantikNaloxegol Oxalate20$8,353
Gabapentin325$5,665
Lidocaine32$4,941
Morphine Sulfate ErMorphine Sulfate137$4,103
ButransBuprenorphine11$3,975
Tizanidine Hcl256$2,825
Oxycodone Hcl127$2,037

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Nucynta, Xtampza Er$515$43,19677 claims
Almatica Pharma LLCGralise$97$13,10512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 124 pain medicine providers in Missouri.

Other pain medicine in Saint Peters

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →